PRE-DIAGNOSTIC SERUM LEVELS OF INFLAMMATORY CYTOKINES IN PATIENTS WITH FIBROMYALGIA
Background: Fibromyalgia is characterised by fatigue, sleep disruption and pain perception. The aetiology of this syndrome is still unclear. Central sensitization is considered to be a major mechanism of action and other factors may be involved including hormonal, genetic and immunological factors. The objective of the present study was to evaluate the role of different interleukins and matrix metalloproteinases in the development of fibromyalgia. Method: Complete blood count (CBC) profile of 50 patients and 50 controls were measured on automated haematology blood analyser. The levels of Interleukins IL-1, IL-2, IL-6, IL-7, IL-8, IL-9, IL-17, IL-18, IL-1β and IL-1-RA were measured using commercially available kits. Matrix metalloproteinases (MMP)-2, 7, and 9 were analysed by ELISA kit assay. Results: The mean values of IL-1, IL-2, IL-6, IL-7 and IL-9 were significantly increased in the patients with fibromyalgia when compared to control individuals. Elevated trends of IL-8, IL-17, IL-18, IL-1β and IL-1-RA were recorded in the patients with fibromyalgia as compared to control individuals respectively. The mean values of MMP-2, MMP-7 and MMP-9 were significantly increased in the patients with fibromyalgia as compared to control individuals. Conclusion The levels of inflammatory markers such as IL-1, IL-2, IL-6, IL-7, IL-8, IL-9, IL-17, IL-18, IL-1β and IL-1-RA were significantly higher among the fibromyalgia patients as compared to controls. These inflammatory markers may have prominent role in the development and progression of disease condition.
Pak J Physiol 2022;18(2):31–4
Bennett RM, Jones J, Turk DJ, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disord 2007;8:27.
Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat 2012;2012:246130.
Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002;46(3):845–7.
Schaefer C, Mann R, Masters ET, Cappelleri JC, Daniel SR, Zlateva G, et al. The comparative burden of chronic widespread pain and fibromyalgia in the United States. Pain Pract 2016;16(5):565–79.
Grayston R, Czanner G, Elhadd K, Goebel A, Frank B, Üçeyler N, et al. A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: Implications for a new paradigm in fibromyalgia etiopathogenesis. Semin Arthritis Rheum 2019;48(5):933–40.
Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550–6.
Aaron LA, Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003;17:563–74.
Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006;67:1219–25.
Geiss A, Rohleder N, Anton F. Evidence for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology 2012;37:671–84.
Borchers AT, Gershwin ME. Fibromyalgia: a critical and comprehensive review. Clin Rev Allergy Immunol 2015;49(2):100–51.
Uceyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011;12:245.
Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine 2022;149:155742.
Pernambuco AP, Schetino LP, Alvim CC, Murad CM, Viana RS, Carvalho LS, et al. Increased levels of IL-17A in patients with fibromyalgia. Clin Exp Rheumatol 2013;31(6 Suppl 79):S60–3.
Bazzichi L, Giacomelli C, De Feo F, Giuliano T, Rossi A, Doveri M, et al. Antipolymer antibody in Italian fibromyalgic patients. Arthritis Res Ther 2007;9(5):R86.
Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, et al. Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J Natl Cancer Inst 1996;88(1):44–9.
Malcangio M, Bowery NG, Flower RJ, Perretti M. Effect of interleukin-1 beta on the release of substance P from rat isolated spinal cord. Eur J Pharmacol 1996;299:113–8.
Carbia-Nagashima A, Arzt E. Intracellular proteins and mechanisms involved in the control of gp130/JAK/STAT cytokine signaling. IUBMB Life 2004;56(2):83–8.
Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001;40:743–9.
Bellinger DL, Lorton D. Autonomic regulation of cellular immune function. Auton Neurosci 2014;182:15–41.
Schwarz YA, Amin RS, Stark JM, Trapnell BC, Wilmott RW. Interleukin-1 receptor antagonist inhibits interleukin-8 expression in A549 respiratory epithelial cell infected in vitro with a replication-deficient recombinant adenovirus vector. Am J Respir Cell Mol Biol 1999:21:388–94.
Hansmann F, Herder V, Kalkuhl A, Haist V, Zhang N, Schaudien D, et al. Matrix metalloproteinase-12 deficiency ameliorates the clinical course and demyelination in Theiler’s murine encephalomyelitis. Acta Neuropathol 2012;124:127–42.
Copyright (c) 2022 Pakistan Journal of Physiology
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Pakistan Journal of Physiology, Pak J Physiol, PJP is FREE for research and academic purposes. It can be freely downloaded and stored, printed, presented, cited and quoted with full reference of, and acknowledgement to the PJP.